Management of Uncontrolled Hypertension on Triple Therapy

Assessment of Current Regimen

The American Heart Association recommends a triple-drug regimen that includes an ACE inhibitor, a thiazide diuretic, and a calcium channel blocker at maximum dose, which represents a good foundation for hypertension management 1, 2
This triple regimen of different drug classes is recommended as an effective combination for hypertension management, with the American College of Cardiology suggesting its use for patients with uncontrolled hypertension 1, 2
Uncontrolled hypertension despite this regimen meets the definition of resistant hypertension, requiring optimization of the current medications before adding a fourth agent, as stated by the American Heart Association 1, 2

The American Heart Association suggests optimizing diuretic therapy by replacing hydrochlorothiazide with chlorthalidone, which has been shown to provide greater 24-hour ambulatory blood pressure reduction, with the largest difference occurring overnight 1, 2
Chlorthalidone should be preferentially used in patients with resistant hypertension due to its superior efficacy compared with hydrochlorothiazide, as recommended by the American College of Cardiology 1, 2

The American Heart Association recommends adding a mineralocorticoid receptor antagonist, such as spironolactone, as the fourth agent if blood pressure remains uncontrolled after optimizing the current regimen, with studies demonstrating significant antihypertensive benefit 3
Spironolactone provides an average additional blood pressure reduction of 25 mm Hg systolic and 12 mm Hg diastolic when added to existing multidrug regimens, with similar benefit in both African American and white patients, as reported by the American College of Cardiology 3

The American Heart Association recommends checking serum electrolytes and renal function within 1 month of adding or increasing the dose of diuretics or ACE inhibitors, with particular attention to potassium levels 3
Monitoring for potential adverse effects of thiazide-like diuretics, including hyponatremia, hypokalemia, elevated uric acid, and elevated calcium levels, is also recommended by the American College of Cardiology 3

The American Heart Association advises against combining an ACE inhibitor with an ARB due to increased risk of hyperkalemia and renal dysfunction without additional blood pressure lowering benefit 3
Considering the timing of medication administration, taking at least one antihypertensive medication at bedtime may improve 24-hour blood pressure control, particularly nighttime blood pressure values, as suggested by the American College of Cardiology 3

In patients with true resistant hypertension (blood pressure uncontrolled despite four antihypertensive agents that include a diuretic), replacing hydrochlorothiazide 100 mg daily with chlorthalidone 25 mg once daily improves 24‑hour blood pressure control and is recommended as the first step in therapy modification. 4
Hydrochlorothiazide doses above 25 mg provide little additional systolic or diastolic reduction while increasing the risk of hypokalemia, hyperglycemia, and hyperuricemia; the maximum advised dose is 50 mg daily. 4
Chlorthalidone’s longer half‑life (≈24–72 h vs ≈6–12 h for hydrochlorothiazide) yields a greater ambulatory blood pressure reduction, especially during nighttime, which is a stronger predictor of cardiovascular events. 4

If blood pressure remains ≥140/90 mmHg after 4 weeks of optimized chlorthalidone therapy, adding spironolactone 25 mg daily (titrating to 50 mg as needed) is advised to achieve target control. 4
Spironolactone produces an average additional reduction of ≈25 mmHg systolic and ≈12 mmHg diastolic when combined with existing multidrug regimens, with comparable efficacy in African‑American and White patients. 4
The drug works by correcting occult volume expansion and aldosterone excess that often underlie treatment resistance even when thiazide‑type diuretics are already used. 4
Serum potassium and creatinine should be re‑checked 2–4 weeks after starting spironolactone, because concurrent use of potassium‑sparing agents such as carvedilol raises the risk of hyperkalaemia. 4

Sodium intake <2 g per day lowers systolic blood pressure by roughly 5–10 mmHg and potentiates the effect of all antihypertensive classes, particularly diuretics and renin‑angiotensin system blockers. 4

Administering at least one antihypertensive medication (e.g., an alpha‑blocker) at bedtime improves 24‑hour control, with the greatest benefit on nocturnal blood pressure, a key determinant of cardiovascular risk. 4
Splitting non‑diuretic antihypertensive agents into twice‑daily dosing can enhance blood pressure control, although the potential gain must be weighed against the possibility of reduced adherence due to regimen complexity. 4

Amiloride 5–10 mg daily, an indirect mineralocorticoid antagonist acting on epithelial sodium channels, yields blood pressure reductions comparable to spironolactone but with a lower incidence of hormonal side effects such as gynecomastia. 4